Before the start of the ESMO congress, MEDSIR has brought together scientists, researchers, pharmaceutical companies, and patient association representatives to...
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune...
SEATTLE WA and LUND, SWEDEN / ACCESSWIRE / September 13, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB...
All-star athletes Naz Reid, Breanna Stewart and Gabby Douglas joining simultaneous celebrations in Minneapolis, New York City and Los Angeles...
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology...
- New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues...
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing...
As the stage is set for another year of groundbreaking research and transformative treatment advancements, several companies are seizing the...
FREMONT, Calif., Sept. 12, 2024 /PRNewswire/ -- The 34th Medical Informatics Europe Conference was held in Athens, Greece August 25-29, 2024....
Northern Nevada health system adopts advanced workforce solutions in support of staff and patient well-being. MCLEAN, Va., Sept. 12, 2024...
Company Leverages Causal Machine Learning to Overcome Key Challenges in Developing New Cancer Treatments BOSTON, Sept. 12, 2024 /PRNewswire/ --...
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials BOSTON and...
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all...
CARY, NC / ACCESSWIRE / September 12, 2024 / Yunu, a leading provider of clinical trial imaging workflow and data...
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the...
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed...
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today...